CTR Georges-François Leclerc
Dijon 21079
3 studies enrolling now · 7 studies all time
What they study most
Biliary Tract Cancer, Bladder Cancer, Colorectal Cancer, Esophageal Adenocarcinoma, Extensive-stage Small Cell Lung Cancer (ES-SCLC), Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Neoplasms, Non-squamous, Non-Small-Cell Lung Cancer
Studies at this site
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread — Recruiting now
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — Recruiting now
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Recruiting now
- A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer — Running, not enrolling
- Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder — Completed
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer — Completed
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours — Completed